Advertisement

In vitro activity of imipenem/relebactam, meropenem/vaborbactam and comparators against Pseudomonas aeruginosa in Taiwan: Results from the Study for Monitoring Antimicrobial Resistance Trends (SMART) in 2020

  • Yuag-Meng Liu
    Affiliations
    Department of Internal Medicine, College of Medicine, Chung Shan Medical University, Taichung, Taiwan

    Department of Internal Medicine, Changhua Christian Hospital, Changhua, Taiwan
    Search for articles by this author
  • Wen-Chien Ko
    Affiliations
    Department of Medicine, College of Medicine, National Cheng Kung University, Tainan, Taiwan
    Search for articles by this author
  • Mao-Wang Ho
    Affiliations
    Division of Infectious Diseases, Department of Internal Medicine, China Medical University Hospital, Taichung, Taiwan
    Search for articles by this author
  • Yu-Lin Lee
    Affiliations
    Department of Internal Medicine, College of Medicine, Chung Shan Medical University, Taichung, Taiwan

    Department of Internal Medicine, Changhua Christian Hospital, Changhua, Taiwan
    Search for articles by this author
  • Po-Ren Hsueh
    Correspondence
    Corresponding author at: Department of Laboratory Medicine, China Medical University Hospital, Taichung, Taiwan.
    Affiliations
    Division of Infectious Diseases, Department of Internal Medicine, China Medical University Hospital, Taichung, Taiwan

    Department of Laboratory Medicine, China Medical University Hospital, Taichung, Taiwan

    School of Medicine, China Medical University, Taichung, Taiwan

    Ph.D. Program in Ageing, School of Medicine, China Medical University, Taichung, Taiwan
    Search for articles by this author
Published:November 02, 2022DOI:https://doi.org/10.1016/j.jinf.2022.10.038
      Dear Editor,
      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to Journal of Infection
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • La Y.
        • Hong J.Y.
        • Lee H.S.
        • Lee E.H.
        • Lee K.H.
        • Song Y.G.
        • et al.
        Increase of multidrug-resistant bacteria after the COVID-19 pandemic in South Korea: time-series analyses of a long-term multicenter cohort.
        J Infect. 2022; (Sep 29:S0163-4453(22)00556-4)
        • Liu Y.M.
        • Chen Y.S.
        • Toh H.S.
        • Huang C.C.
        • Lee Y.L.
        • Ho C.M.
        • et al.
        In vitro susceptibilities of non-Enterobacteriaceae isolates from patients with intra-abdominal infections in the Asia-Pacific region from 2003 to 2010: results from the Study for Monitoring Antimicrobial Resistance Trends (SMART).
        Int J Antimicrob Agents. 2012; 40 (Suppl): S11-S17
        • Bassetti M.
        • Vena A.
        • Croxatto A.
        • Righi E.
        • Guery B.
        How to manage Pseudomonas aeruginosa infections.
        Drugs Context. 2018; 7212527
        • Moyá B.
        • Beceiro A.
        • Cabot G.
        • Juan C.
        • Zamorano L.
        • Alberti S.
        • et al.
        Pan-β-lactam resistance development in Pseudomonas aeruginosa clinical strains: molecular mechanisms, penicillin-binding protein profiles, and binding affinities.
        Antimicrob Agents Chemother. 2012; 56: 4771-4778
        • Feng W.
        • Huang Q.
        • Wang Y.
        • Yuan Q.
        • Li X.
        • Xia P.
        • et al.
        Changes in the resistance and epidemiological characteristics of Pseudomonas aeruginosa during a ten-year period.
        J Microbiol Immunol Infect. 2021; 54: 261-266
        • Hsueh P.R.
        Study for Monitoring Antimicrobial Resistance Trends (SMART) in the Asia-Pacific region, 2002-2010.
        Int J Antimicrob Agents. 2012; 40 (Suppl): S1-S3
        • Lee Y.L.
        • Lu M.C.
        • Shao P.L.
        • Lu P.L.
        • Chen Y.H.
        • Cheng S.H.
        • et al.
        Nationwide surveillance of antimicrobial resistance among clinically important Gram-negative bacteria, with an emphasis on carbapenems and colistin: results from the Surveillance of Multicenter Antimicrobial Resistance in Taiwan (SMART) in 2018.
        Int J Antimicrob Agents. 2019; 54: 318-328
        • Jean S.S.
        • Lu M.C.
        • Ho M.W.
        • Ko W.C.
        • Hsueh P.R.
        Non-susceptibilities to antibiotics against important Gram-negative bacteria, and imipenem-relebactam, meropenem-vaborbactam against carbapenem non-susceptible Enterobacterales and Pseudomonas aeruginosa isolates implicated in complicated intra-abdominal and urinary tract infections in Taiwan, 2019.
        J Microbiol Immunol Infect. 2022; 59106521
        • Teo J.Q.
        • Tang C.Y.
        • Lim J.C.
        • Lee S.J.
        • Tan S.H.
        • Koh T.H.
        • et al.
        Genomic characterization of carbapenem-non-susceptible Pseudomonas aeruginosa in Singapore.
        Emerg Microbes Infect. 2021; 10: 1706-1716
        • Lob S.H.
        • Hoban D.J.
        • Young K.
        • Motyl M.R.
        • Sahm D.F.
        Activity of ceftolozane-tazobactam and comparators against Pseudomonas aeruginosa from patients in different risk strata - SMART United States 2016-2017.
        J Glob Antimicrob Resist. 2020; 20: 209